TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15330779
Drug: Outdoor air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outdoor air supply rate at 10 l/s/p and temperature at 24.5 degrees C
Study: 15330779
Drug: Outdoor air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outdoor air supply rate at 5 l/s/p and temperature at 22.5 degrees C
Study: 15330779
Drug: Outdoor air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outdoor air supply rate at 5 l/s/p and temperature at 24.5 degrees C
Study: 15330779
Drug: Temperature reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature reduction from 24.5 degrees C to 22.5 degrees C at 10 l/s/p
Study: 11094581
Drug: Amiodarone (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (900 mg per 24 h)
Study: 11094581
Drug: Magnesium (4
Normalized name: magnesium oxide 265.3 mg magnesium (440 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (4 g per 24 h)
Study: 11094581
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl; 50 ml per 24 h)
Study: 8833058
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (MTX 17.5 mg/week, sulfasalazine 500 mg bid, hydroxychloroquine 200 mg bid)
Study: 8833058
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxychloroquine and sulfasalazine
Study: 1430130
Drug: Gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone agonist (GnRHa) in the midluteal phase coupled with follicular phase administration of human menopausal gonadotrophin
Study: 3908501
Drug: carteolol 5
Normalized name: CARTEOLOL 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: carteolol 5 mg
Study: 3908501
Drug: carteolol 20
Normalized name: carteolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: carteolol 20 mg
Study: 31751183
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg bid)
Study: 28741804
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein group (1.2 g/kg per day protein diet + 25% additional whey protein supplement)
Study: 28741804
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (1.2 g/kg per day protein diet without additional whey protein supplementation)
Study: 23130909
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (400 mg) plus folic acid (600 µg)
Study: 23130909
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (ferrous sulfate with folic acid)
Study: 23130909
Drug: Both intravenous
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intravenous iron and oral iron
Study: 17133559
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg) with methotrexate
Study: 14535876
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Study: 14535876
Drug: Antimicrobial sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial sensitivity testing-based treatment with ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Study: 14535876
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg b.d., clarithromycin, 500 mg b.d., and amoxicillin, 1 g b.d.
Study: 14535876
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate, 400 mg b.d., tinidazole, 500 mg b.d., and clarithromycin, 500 mg b.d.
Study: 10746516
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg magnesium + 50 mg vitamin B6
Study: 9545899
Drug: 0.06% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% chlorhexidine irrigation using a powered oral irrigator (Water Pik)
Study: 9545899
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine gluconate rinsing once daily
Study: 1408551
Drug: Planned bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned bottle group (one bottle daily between the second and sixth weeks postpartum)
Study: 30528222
Drug: Cabozantinib 60mg
Normalized name: CABOZANTINIB 60MG TAB
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib 60mg once daily orally
Study: 30528222
Drug: Mitoxantrone 12mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone 12mg/m2 every 3 weeks plus prednisone 5mg twice daily orally
Study: 28903131
Drug: Fluorouracil-based adjuvant
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based adjuvant chemotherapy in MGMT-positive patients
Study: 19698734
Drug: GVG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GVG (1 g/day increased to 5 g/day)
Study: 15025222
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline (20 mg) b.i.d. for 3 months plus scaling and root planing (SRP)
Study: 15025222
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules b.i.d. for 3 months plus scaling and root planing (SRP)
Study: 11597949
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E at 300 mg/d during dinner (group B)
Study: 11597949
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E at 300 mg/d on an empty stomach (group A)
Study: 8624429
Drug: Nafarelin acetate
Normalized name: Nafarelin Acetate
DrugBank: Nafarelin (DB00666)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nafarelin acetate 600 micrograms/daily
Study: 8624429
Drug: D-Trp6-LHRH 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Trp6-LHRH 0.5 mg/daily
Study: 2722135
Drug: Oral fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fructose load
Study: 141471
Drug: Aerosolized atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized atropine sulfate (1 mg)
Study: 31871257
Drug: Dry cupping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry cupping therapy application with two suctions, performed once a week for 8 weeks.
Study: 31871257
Drug: Placebo dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dry cupping therapy, performed once a week for 8 weeks.
Study: 23986166
Drug: Test formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formula containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water applied twice daily for 4 weeks as monotherapy
Study: 23986166
Drug: Test formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formula applied twice daily for 8 weeks as adjunctive therapy
Study: 23986166
Drug: Vehicle control
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control applied twice daily for 8 weeks
Study: 21074790
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg desmopressin orally at bedtime
Study: 15196307
Drug: Training module
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training module and administration of the guideline (Arm 1)
Study: 15196307
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of guideline without training (Arm 2)
Study: 11758228
Drug: Tpo levels
Normalized name: Tpoxx
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tpo levels in CITP patients with glucocorticoid therapy response
Study: 9127923
Drug: Epidural blockade
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blockade with 20 ml of 0.25% bupivacaine
Study: 3284457
Drug: Ceftazidime (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (30 mg/kg)
Study: 3284457
Drug: Cefoperazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone (30 mg/kg)
Study: 23216423
Drug: Betrixaban 80
Normalized name: betrixaban 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban 80 mg
Study: 23216423
Drug: Betrixaban 140
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 140 mg
Study: 19238715
Drug: Kangaroo Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo Care (KC) for 10 min before the injection and during the procedure
Study: 16572350
Drug: Norepinephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine infusion (NE)
Study: 12944340
Drug: Therapeutic effects
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic effects of treatment
Study: 9211675
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of elemental calcium
Study: 28682183
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use at baseline
Study: 21302036
Drug: NIPRD-AM1 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPRD-AM1 (250 mg×2) with metronidazole (200 mg×2)
Study: 21302036
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg×2) alone
Study: 17009630
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue treatment
Study: 12657164
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus SU5416 (VEGF receptor tyrosine kinase inhibitor)
Study: 6454395
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with 13‐cis retinoic acid
Study: 30910894
Drug: DSTA4637S (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTA4637S (5, 15, 50, 100, and 150 mg/kg)
Study: 28328705
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 650 nm, administered every other day for 17 weeks
Study: 25829373
Drug: Intravenous fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosfomycin (4 g/6 h)
Study: 23949025
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy with sequential target presentation
Study: 23949025
Drug: Robot-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted therapy with random target presentation
Study: 17655805
Drug: rTMS (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (10 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Study: 17655805
Drug: rTMS (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS (20 sessions of daily stimulation over the left dorsolateral prefrontal cortex)
Study: 15175560
Drug: Terbutaline (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (large intravenous doses)
Study: 11355926
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation treatment with high-dose Ara-C
Study: 9935255
Drug: Trovafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trovafloxacin (200 mg) with Morphine (0.15 mg/kg)
Study: 1303534
Drug: Morphine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.15 mg/kg)
Study: 9052509
Drug: Omeprazole therapy
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole therapy for eight weeks
Study: 2476613
Drug: Controlled-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily
Study: 2476613
Drug: Controlled-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release isosorbide-5-mononitrate (ISMN-CR) 60 mg twice daily
Study: 786379
Drug: Oral papaverine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral papaverine (300 mg b.i.d.)
Study: 19308305
Drug: Natalizumab in
Normalized name: natalizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab in treatment-naive patients with highly active disease
Study: 19308305
Drug: Natalizumab in
Normalized name: natalizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab in patients with highly active disease despite IFNbeta-1a treatment
Study: 8350329
Drug: Leucovorin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin (1 mg)
Study: 2871058
Drug: Clonidine, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.4 mg/day
Study: 27000036
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation (eight weekly sessions)
Study: 27000036
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (eight weekly sessions)
Study: 24119199
Drug: CoQ10 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (200 mg/day)
Study: 19419253
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor and diuretic combination
Study: 7870011
Drug: HuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuEPO treatment for anemia in preterm infants
Study: 30392080
Drug: aPDT adjunct
Approvals — FDA: no, EMA: no, PMDA: no
Description: aPDT adjunct to SRP
Study: 21896619
Drug: Ordinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary treatment (Control)
Study: 15369941
Drug: Pinch technique
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinch technique before and during DMPA injection
Study: 15369941
Drug: Injection only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection only (control group)
Study: 11600531
Drug: Tibolone 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 0.3 mg daily
Study: 11600531
Drug: Tibolone 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 0.625 mg daily
Study: 11600531
Drug: Tibolone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 1.25 mg daily
Study: 2459988
Drug: Atracurium (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (dosage not specified)
Study: 241119
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin stearate (500 mg twice or 3 times a day for 10 days)
Study: 26144593
Drug: Cannabis-alcohol combination
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis-alcohol combination (5μg/L THC + 0.05g/210L alcohol)
Study: 21401541
Drug: Ocular compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular compression using an external pressure device for 20 min before combined peri- and retrobulbar injection
Study: 19336453
Drug: Raltegravir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (400 mg twice a day) plus optimized background therapy (OBT)
Study: 17353499
Drug: High-fiber DASH
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber DASH diet (30 g/d)
Study: 17353499
Drug: Fiber-supplemented diet
Normalized name: FIBERMED HIGH-FIBER SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-supplemented diet (30 g/d)
Study: 8172146
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. plus amoxicillin 1 g b.i.d. (group I; n = 35)
Study: 8172146
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg b.i.d. plus amoxicillin 1 g b.i.d. (group II; n = 35)
Study: 31661579
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with 12 weeks of education (I-group)
Study: 31661579
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (C-group)
Study: 29622380
Drug: Tralokinumab 600
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab 600 mg
Study: 29622380
Drug: Tralokinumab (150,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (150, 300, or 600 mg)
Study: 29622380
Drug: Tralokinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (300 mg)
Study: 28258661
Drug: G-CEM LinkAceTM
Normalized name: CEM-Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CEM LinkAceTM
Study: 25328082
Drug: G. kola
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. kola 12.5 g once daily for 7 days (group A)
Study: 25328082
Drug: G. kola
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. kola 12.5 g twice daily for 6 days and once on the seventh day (group B)
Study: 25328082
Drug: Quinine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine with G. kola
Study: 1587589
Drug: EcSf2a-1 vaccine
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-1 vaccine (1.0 x 10(9) CFU)
Study: 1587589
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (1.5 x 10(11) CFU in three doses)
Study: 1587589
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (2.5 x 10(9) CFU)
Study: 1587589
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (1.8 x 10(10) CFU)
Study: 1587589
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (1.2 to 2.5 x 10(9) CFU in three doses)
Study: 24849793
Drug: Wii Sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii Sports Resort training plus usual therapy
Study: 15758622
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 3 mg enema once daily for 6 weeks
Study: 15758622
Drug: 5-ASA (mesalamine)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-ASA (mesalamine) 1 g enema daily for 6 weeks
Study: 10323605
Drug: HGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGH (0.1 mg/kg/day)
Study: 12637255
Drug: Oxandrolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (20 mg/day)
Study: 8759894
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idarubicin (IDR) (8 mg/m2, i.v., days 1-5)
Study: 8759894
Drug: Zorubicin (ZRB)
Normalized name: zorubicin
DrugBank: Zorubicin (DB11618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zorubicin (ZRB) (200 mg/m2, i.v., days 1-4)
Study: 8759894
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy with high-dose Ara-C (3 g/m2, 3 h infusion, q 12 h, days 1-4) and m-Amsa (100 mg/m2/d, i.v., days 5-7)
Study: 6352185
Drug: Indapamide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.0 mg/day for 4 weeks
Study: 6352185
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg/day for 4 weeks
Study: 6352185
Drug: Indapamide 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 5.0 mg/day for 4 weeks
Study: 6352185
Drug: Indapamide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (all doses)
Study: 26909960
Drug: Tripterygium wilfordii
Normalized name: TRIPTERYGIUM WILFORDII ROOT
DrugBank: Tripterygium wilfordii whole (DB14277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium wilfordii pills (orally administered) for three courses of treatment, each consisting of 4 weeks, in addition to conventional western medicine.
Study: 26909960
Drug: Observation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation group (T. wilfordii + conventional medicine).
Study: 26909960
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional medicine).
Study: 22382219
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9%) hydration at 1 mL/kg/h for 12 hours before and 24 hours after PCI
Study: 20801446
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplementation
Study: 17096666
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg/ml intravenously every 6 h during the first post-operative day (total, 400 mg/24 h)
Study: 2104438
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of sodium heparin
Study: 2104438
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of sodium heparin
Study: 697222
Drug: Smoking marihuana
Normalized name: Picea mariana resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking marihuana cigarettes containing 6 mg of delta‐9‐tetrahydrocannabinol